Alison Murphy

TL;DR: Systemic SD-208 treatment initiated 3 days after the implantation of SMA-560 cells into the brains of syngeneic VM/Dk mice prolongs their median survival from 18.6 to 25.1 days, and animals responding toSD-208 showed an increased tumor infiltration by natural killer cells, CD8 T cells, and macrophages.

TL;DR: Significant promise is shown of the development of an effective therapeutic intervention for IPF and that inhibition of chronic progressive fibrosis may be achieved by blocking TGF-beta receptor activation.

TL;DR: TGF-β type I receptor kinase inhibitors hold promise as novel therapeutic agents for metastatic breast cancer after testing their effects on two murine mammary carcinoma cell lines in vitro and in vivo.

TL;DR: In this paper, a 2,4-disubstituted pteridine, ATP-competitive inhibitor of the TGFβ receptor I kinase (TGFβRI) was used to inhibit cellular activities and tumor progression of PANC-1, a human pancreatic tumor line.

TL;DR: Evidence is provided that increased TGF-beta signaling participates in the pathogenesis of experimental severe PH, with a small but significant improvement in hemodynamic parameters and medial remodeling.